Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Terveystalo, Q2'24

By Inderes7/17/2024, 7:30 AM
Terveystalo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Katie Coxon
00:01 - 00:36

Good morning, everybody, and welcome to the first half-year results webcast and phone conference. My name is Katie Coxon, and I am responsible for investor relations, sustainability, and communications. As usual, we'll have the presentation held first by our CEO, Ville Iho. And then the results analysis will be followed by our CFO, Juuso Pajunen. After that, we'll have time for your questions. We'll take questions from the phone lines as well as through the webcast after the presentations. Without further ado, over to you, Ville.

Ville Iho
00:37 - 05:52

Thanks, Katie, and from my side as well. Very good job done. And hopefully it's a sunny July morning in Helsinki. I have the great pleasure to present the Q2 results today. We can say that this is the strongest second quarter ever in our company's history. And it's not just one number; it's across the board, great results and strong, consistent development against our targets. Healthcare services, our biggest business, is driving the positive development and momentum, both in top-line and margin growth. We are very glad to see that the portfolio businesses where we have started. Individual profitability improvement initiatives in respective businesses are also improving and contributing to the group's progress results. In Sweden, we don't yet see the full results. But we are very pleased to see how the agenda has been evolving and how committed and determined the work the team in Sweden is, and we are confident that the same pattern will follow in Sweden. We will turn around the business in 2025, and this all comes with the backdrop of continued high quality. Our Net Promoter Score (NPS) is at a record high level. Also, medical quality is improving, which is very important for the future of our business and business model. Key numbers are set, no matter where you look, this is extremely strong. Quarter-over-quarter continues on the path set for transformative 20 months ago with the profitability improvement program. Revenue is up by some 5%, driven by healthcare services, EPS shows strong improvement with 91% EBIT at 42.5 million and a 50% improvement year-on-year, and EBITDA margin at 12.5%. As I said, an 86.4% improvement from a very high level as well. And we continue creating strong cash flow with the profitability. All in all, as I said, record quarter. But this is not where we want to end. This is the second quarter in a row where we can see that we are at a new, higher level. And from this level, we continue progressing. Our balance, our segments. Presented in graphical format, healthcare services are leading the race. The agenda for that was set some 20 months ago with the Alpha program showing great improvement from last year to this second quarter in portfolio businesses, as mentioned, is starting to improve. And that's of course very important for the company. It's not only one cylinder that is contributing; it's already two and it will be three as we turn around the Swedish business in the course of the next 12 countries. In the future, it's important to see the progress that we are making and also the phasing of that progress. In this slide, you can see the different panels in order of magnitude. But this is not only about the order of magnitude. This is also about the phasing of our program. Healthcare services are now set at a new high level, but they continue to improve. And we see further potential there with a new agenda. Portfolio of businesses, as I said, has started to improve. And there's a new, ambitious target set for each business. And we are determinedly progressing towards those targets. In Sweden, we will turn around and these three cylinders at the end will contribute to their best future. This is very important for our story and also supports the new guidance that Juuso will walk you through in detail in a few minutes. This also, of course, begs the question, what's next for the reversal? We are now at a new level and we see further potential. And we invite you to listen. Listen to our new agenda and a new set of targets on December 4th this year with that one. Over to you, Juuso.

Juuso Pajunen
05:52 - 16:21

Thank you, Ville. So let's talk about the critical aspect of our quarterly release. So that's the numbers. Obviously a week ago we disclosed some preliminary results, which diminished some of the suspense for this presentation. But I'm really proud and happy to show what we are achieving at the moment. So if we consider the highlights, we have continued the margin recovery in Q2. Actually, this was the best Q2 in the company's listed history. When it comes to relative margin? We are seeing our adjusted EBITDA increase by 49%; earnings per share by 91. Or if you consider the half-year earnings per share, it has more than doubled. Our leverage stands at 2.5. What does this include regarding IFRS 16? So no matter how you look at this performance, it's solid. You can pick a line in the income statement. You can pick a line in the balance sheet or you can combine those and we are on track. And as we mentioned, it's not only the financial performance, but we also have the NPS customer satisfaction. We have the medical quality pace. All of these are strong and solid. So we are truly delivering now. Our performance is coming from the Finnish segments and, especially from the healthcare services, which you will see further when we move forward in the slides. Sweden is not visible in the figures, but we have a very clear agenda. We have taken solid steps forward and we are very confident about the progress of our profit improvement program. So it will be coming in 2025. And all of this merits the guidance update. We will be between 11.5 and 12.5 at the end of this year. So, if we then look a bit at the revenue, basically you could read the headline: Profit Improvement Program - Commercial actions delivering. We are growing 5.5%. One needs to remember that we had one working day more in the second quarter compared to the previous quarter. That helps slightly with that growth. So the volume adjusted appointment growth or workday adjusted appointment growth is not heavily growing. It's stable, even though it is 1.4% during the quarter in absolute terms, but that supports the growth. Then we have both the customer and service mix working in our favor. We need to remember also that this is a low demand month or low demand quarter, as is the third quarter, which affects diagnostics and other service sales. So the appointment delivery is more significant and the appointment performance may be better than in Q1 and Q4. And it's worth noting that revenue is increasing in all customer groups and in all services. So we are consistently improving our healthcare services in terms of portfolio businesses. We have the outsourcing decline. We have communicated, you are all aware, and it continues on the anticipated pace. Staffing continues on the track from Q1. We have been doing some proactive customer selection. We don't want to offer just anything, we want to offer those services where we have solid value, which also converts into profit. And then what comes to dental and massage? We are continuously impacted by the lower consumer purchasing power. The decline has stabilized, but the trend is still very wobbly. It would be difficult to say that it is clearly demonstrating improvement, but it has clearly stabilized during the year and most likely bottomed out during Q1. Then, if we look at Sweden and also consider the story continued, we have ended customer contracts, customer selection, but also a weak demand environment, which is hitting our business model more than in our Finnish business. So all in all, 5.5% growth, very solid growth in our healthcare services, which is the big moat and basically matching improving customer selection and revenue selection, especially in portfolio businesses and Sweden. Then, if we observe the appetite development adjusted EBITDA from 28.5 to 42.5. Almost 50% improvement. We have healthcare services truly delivering. We are clearly seeing the operational efficiency. And here I want to highlight continuously that it's the low demand season and during that season, the ability to yield margin through all of the services with a sales mix capability is very important. And this is what we have demonstrated now with our profit improvement program that has progressed quicker than anticipated but also delivers very solidly. So this one, combined with the successful commercial actions and the continued scrutiny on cost, delivers the profit improvement. In our portfolio businesses, we see positive development in staffing and outsourcing. And here, we also see the commercial actions. We have the operational efficiency improvements. But then it's significant to note that we have been fairly solid and effective in adjusting our consumer-driven businesses to the lower demand. So once the demand starts to pick up, we are lean and prepared to move forward. Also in that respect, and finally in Sweden, the reduction in revenues converts into bottom line. But as stated, the profit improvement program is progressing. Then finally, it's important to note that it's not an adjusted EBITDA topic, but in the adjustment items as mentioned in our profit warning last week, we have a roughly €6 million additional item related to renovation liabilities from a rental contract. This contract is older than a decade. So, that is truly not for this period. And we don't have similar types of items in our portfolio. So that's good to note. Looking at our total numbers going into the sales mix that has improved in Finland, we continue to face headwinds in Sweden. There’s nothing particularly new that I wouldn’t have already mentioned earlier, but as said, it’s good to note that in healthcare services all client segments are growing. All services are growing from a revenue perspective and margin creation is really solid. Portfolio business is a bit of a mixed bag, but the revenues are declining in the public sector by choice and in the consumer segments from the market environment. If we then look at H1 as a total, this story continues. Revenues are growing by 4%. So now, no data adjustments are needed. We don't have these types of shows fully comparable year on year; appointments are up by 4%. Uh, a bit less than 1%. It's down. And despite that, we are improving our adjusted EBITDA by 38%. The big contribution comes from healthcare services and portfolio businesses. Uh, still, we are moving towards better and more profitable momentum. And Sweden is in the early stages of the profit improvement program. So it's very natural and understandable, presenting a consistent story with Q1 and Q2. So very consistent, very understandable in my opinion. Then, if we look at cash flow, when we make profit, we generate cash. As simple as that. The clock is ticking. We have a really strong EBITDA and really strong cash flow. We have been fairly conservative on the CapEx side, with -38 million LTM. We continue to be slightly below our own expectations. Maybe, but at the same time, we are doing what is the right thing. We are investing in digital technologies. We are investing in our facilities. And, uh, that's pretty much that. Then, if we look at our leverage, 2.5 continued improvement in the leverage ratio, with interest-bearing liabilities going slightly down. And it's good to note that in Q2, we paid out our dividends. And we have already funded that with operating cash flow. So it's a solid place from which to convert into cash, which is how it always should be. So then we move to the guidance. We expect revenues to grow. There's no change in their adjusted EBITDA, expected to be between 11.5 and 12.5. As you note, the midpoint is at 12%. So, 20 months ago we said we would reach 12% in 2025. Now there is a clear likelihood that we could achieve this already in 2024. Our estimates are based on everything we know at the end of the second quarter. So inflation, consumer demand, employment, and normal morbidity. So still, for Q4, we expect a normal flu season. That's important for our profit generation. We are confident that our performance improvement program continues to deliver and is sustainable. And then we have the same disclaimers as earlier. So all in all, we are very confident in our visibility. We are confident in our first delivery and we are confident in our future delivery. And with these numbers, it's easy to say that 11.5 to 12.5 represents a clear improvement compared to the Q1 release, a clear improvement from the start of the year. And that's where we are with these words. Any final words will conclude it.

Ville Iho
16:21 - 16:45

No. It's, um, a big thanks to the terrific startup team for delivering these results over the last 20 months. Literally, there have been thousands of people contributing, both on the front line and in the back office, to these achievements and a bright future ahead.

Katie Coxon
16:46 - 16:51

Absolutely. So now we have time for your questions. Do we have any questions on the phone lines?

Operator
16:56 - 17:19

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Joanie Sandoval from Nordica. Please go ahead.

Unknown
17:21 - 17:43

Yeah. Thanks. Just for the good presentation and, uh, good results. Congratulations on those. Um, maybe starting with the, uh, quite strong corporate sales growth. And it was clearly picking up from Q1. So what is actually driving the growth? Is it the pricing component, or have you just been successful on the commercial front?

Juuso Pajunen
17:44 - 17:46

Uh, Juuso, do you want to start?

Ville Iho
17:46 - 17:47

Well, you can start.

Juuso Pajunen
17:48 - 18:07

Yeah. So basically, if you look at the corporate revenues purely from a numbers perspective, the connected employees are now slightly improving after Q1. We have one working day more. So those are the mathematical components. But then we have an improved client mix. And of course the pricing and commercial actions that are also contributing to the growth.

Ville Iho
18:08 - 18:33

Yeah. And, as we have discussed earlier, when we think about the commercial actions, it's not solely about headline price increases. Of course, that's a contributing factor, but there are different elements on how we slice and dice the commercial offering and how we, for example, address price leakages and improve on that front.

Unknown
18:36 - 18:53

Okay. Okay. Thanks. Uh, then maybe, maybe on the appointments and your new remuneration plan that you launched earlier this year. Has this actually progressed faster than you had earlier anticipated?

Ville Iho
18:54 - 19:33

Yes, one can say that it's slightly above our expectations. The contribution mix has been slightly different and better from our angle. It's not fast because it's a sequence of actions that we chose to do, and then we see the impact. So there's some more to come. During the course of this year.

Unknown
19:34 - 19:54

Okay, thanks. Then, one question about the diagnostic sales. Obviously, it's a quieter quarter now, but sales growth has improved there. Are there any improvements in the funneling on this front, and how should we think about the growth rates going forward for H2?

Ville Iho
19:57 - 20:43

If we start from sort of a longer-term perspective, and the discussions we have had over the past 20 months, there's no drastic change to be expected in how the appointments are then contributing to diagnostic sales. We have been able to improve the digital appointment conversion to diagnostics. There's some work to be done when we think about the rest of the pool, and we are steadily progressing, mainly due to the flow seasons and such. What exactly is the customer demand?

Unknown
20:45 - 21:12

Okay, maybe one question on healthcare services' margin improvement potential. You mentioned that there is still an improving trend in profitability. But how much of this is directly related to the profit improvement program, and how much is just, you know, normal business improvement that you are expecting?

Ville Iho
21:13 - 21:47

Well, of course, that's a bit of a theoretical question, because now we are in the middle of, uh, a transition or actually we have already completed the handover from the Profit Improvement Program in Healthcare Services to the line organization. It's a blend of new actions in the agenda of healthcare services and the tail end of Alpha initiatives. As I mentioned earlier, there's continued progress and, of course, we have not fully emptied the tank yet.

Juuso Pajunen
21:48 - 22:13

We don't break it down on a segment level, but obviously, to achieve an 11.5 to 12.5 target this year, it implies that there's also a contribution from healthcare services. As previously mentioned, we are not expecting any material improvements from Sweden this year, especially compared to the previous year, and portfolios are progressing at their own pace. Of course, healthcare services will continue to contribute positively.

Unknown
22:16 - 22:31

Last question from my side. On the M&A front, now that the profitability levels have been restored or improved, how is your M&A appetite going forward?

Ville Iho
22:32 - 23:55

Well, a recipe for success. Over the last 20 months, we have been keeping our eye on the ball. As we discussed in the presentation, facing important healthcare services is crucial. During the last two quarters. It has been on a new level. We see further potential there, and we can claim it is a solid and good base for future progress. So, if we see opportunities on that front, of course, there is no reason not to pursue those portfolios. It's a slightly different story in that they have started later and are now progressing, which is very good for the whole group. We need to be very, very selective in what we undertake. There are further considerations also in that mix, how we deem each and every business going forward. But what is important is that it's improving and continues to improve. Lastly, Sweden has totally kept its eye on the ball with its agenda. So, we'll concentrate now solely on delivering the results through the profit improvement program in our Swedish business, and then, when the time is right, we will return to this M&A discussion.

Unknown
23:57 - 23:59

Okay.

Operator
24:05 - 24:11

The next question comes from Sami Sarkamo from Danske Bank. Welcome, everyone, to our webcast presentation covering Terveystalo Group's financial performance for the first half of 2024.

Unknown 1
24:15 - 24:47

Okay. We'll take this one by one. Firstly, starting from seasonality, how should we think about this going forward? In the past, the second and third quarters have tended to be quite a bit weaker than Q1 and Q4. Now, the second quarter was actually quite strong relative to the first quarter. What are your thoughts on seasonality at the moment?

Juuso Pajunen
24:50 - 26:07

Well, first, if we now look purely at the technical part of the seasonality, we have one working day more in Q3 compared to the previous year, which actually comes from July. It's traditionally more difficult to evaluate the technical impact because it occurs during the vacation period. The Q4 is flat, with the same 62 working days. In that sense, we have a bit of positive momentum coming for the second half from the working days. The second part of the seasonality particularly relates to the flu season, which makes Q4 and Q1 strong periods. That one obviously remains, as their Q3 will be seasonally weak. That one will not go away. A significant achievement of our profit improvement program is that we are now clearly better at generating margins from appointments. And once we have an appointment-heavy Q3, I think that we have all the room to improve in Q3, but obviously, it will still be seasonally weaker than other quarters. So maybe not as much volatility as sometimes seen in history, but the underlying reasons for seasonality have not actually vanished.

Unknown 1
26:10 - 26:31

That's very helpful. Um, and then the second question would be on the diagnostics area where you achieved 8% revenue growth on the back of 1% volume growth. Was there anything special in the second quarter, or have you raised prices this much overall?

Ville Iho
26:33 - 26:46

No, it's, uh, as you said earlier, it's a mix. It's the price of that combination. Additionally, we've noticed a slight improvement in conversion in what we are doing.

Unknown 1
26:51 - 27:13

Okay. And thirdly, you reported quite negative trends at a portfolio basis. Overall, we experienced negative growth rates not only in outsourcing services, but also in staffing and dental care. Do you see any potential for improvement in staffing or dental care during the second half of the year?

Ville Iho
27:14 - 28:59

Well, to start with, particularly in dental care, as we have discussed earlier, it is suffering from issues like consumer confidence and disposable income challenges. As you mentioned, the trend has stabilized. We don't see a growth trend in consumer demand yet, at least not a substantial one. However, it has stabilized. The good thing about dental care is that we have been able to protect the margins and even improve them, even though the consumer demand environment has been flat or even negative. We have made a conscious decision to continue focusing on and investing in dental care. We see potential there as it's an area of business in healthcare that we believe in. However, it will take some time for this consumer trend to turn around. For staffing, as you mentioned, we have been more selective and tougher on pricing, which can be seen in the volume of contracts. We are pleased with the profitability progress in that area. It's going to remain a stable part of our business. It has been very stable. Healthcare districts, regardless of the discussion and comments around staffing, will need these services. The way we deliver these services is sustainable and contributes to healthcare districts' services and their duties.

Unknown 1
29:02 - 29:04

Okay, thanks. I don't have any further questions.

Operator
29:11 - 29:16

There are no more questions at this time, so I hand the conference back to the speakers.

Katie Coxon
29:18 - 29:44

Thanks. We have some questions from the webcast audience. So, maybe starting with the results and the forward-looking view. Congratulations on the great result in a challenging market. That is difficult for many companies in general. The question is, is there still room for even better results in the coming quarters, or have we now reached our peak?

Ville Iho
29:45 - 30:19

This year, we have upgraded our guidance twice. So, that speaks for itself. Now we have the guidance in place. A user commented that we see, thoroughly, we are ahead of our schedule in our profit improvement program. That's clear and that's what lies ahead for the reversal with our strong progress and strong cash flow, which we will address in our Capital Markets Day later this year in December.

Juuso Pajunen
30:20 - 30:32

And then purely mathematically, it's good to note that our last 12 months EBITDA is 11.4 and we are guiding 11.5 to 12.5. So, we are definitely guiding continued improvement.

Katie Coxon
30:34 - 30:50

Yes, then maybe talking about the risks and the top-line growth. Are there any identifiable risks? For the business for the rest of the year? And what about the top line growth expectations? Are we expecting continued growth there?

Ville Iho
30:51 - 31:24

I will refer back to the guidance and use the comments around that one. Also, the guidance comments and caveats made are very clear. They are very clear. So there are no new issues on the horizon. It has not been a booming market on many fronts, but we have been able to progress regardless. We see steady progress ahead.

Katie Coxon
31:28 - 31:48

Then maybe jumping into M&A, which we briefly discussed already. Are we looking at any new M&A activity for this year and what kind of targets would be the ideal fit for our portfolio? Maybe first to you.

Juuso Pajunen
31:48 - 32:33

As we explained briefly earlier, our three businesses are in different phases. And depending on which phase you are in, the more you have earned to also acquire. We are interested in making acquisitions that fit into our strategy and core offering. Should these type of opportunities emerge, or should we be able to create those opportunities ourselves? Of course, we are willing to grasp them, and we have the balance to do it. At the same time, our main focus is still to deliver solid returns to our shareholders. We would not jump into an acquisition just for the sake of growth unless it truly yields an EPS increase.

Katie Coxon
32:37 - 32:55

Then, a question from Carnegie: Volumes in healthcare services have started to grow year-on-year after a declining trend in early 2023. Do we see this growth as being sustainable? And what are the drivers behind the volume growth?

Juuso Pajunen
32:56 - 33:46

If I may start, technically, volumes are stable. Even though we have seen appointment growth in healthcare services in Q2, it's important to remember there's one more working day, which technically contributes to some of the appointment growth. H1 figures were at 99.7 or 99.1, if I recall correctly, compared to previous years. So we have not yet reached a position where we would say that we have a solid volume growth in our portfolio. As you look month by month, there are some indications that suggest we could see positive developments ahead, but it's still too early to confirm. So I would describe our volumes as stable at the moment.

Ville Iho
33:49 - 33:50

Nothing to add.

Katie Coxon
33:50 - 34:08

All right, then, a question on the cash flow profile and capital allocation. As we commented, the cash flow profile is strong, which is generally a bit rare in these times. The question is, are we more inclined to grow dividends or invest in growth going forward?

Juuso Pajunen
34:09 - 35:10

Yes, I think the first and easy answer to that one is to stay tuned. Capital Markets Day on December 4th. Then, if we look a bit backwards, what has happened is that we have continued to deliver solid cash flow. We had an EPS return on equity perspective, a difficult year in 2023 due to non-cash related write-offs. But even after adjusting for those, we paid a solid dividend. I think that has been an indication from the board of directors that they rely on our cash generation and that they are willing to share the positives with shareholders. So, there is no change in this logic, nor logic in our capital allocation. We can invest either in walls, digital, MTA, or give money back to our shareholders. And we have been fairly consistent in all of those areas at the moment. So let's wait until the Capital Markets acronyms of day and maybe we can also think about that topic.

Katie Coxon
35:13 - 35:27

All right then, still a couple more questions. First, on the pricing environment, what sort of our early thinking going ahead to next year about pricing and how we see that.

Ville Iho
35:28 - 36:32

That's of course a very important topic for our commercial team. What we see in the market, we have been slightly more aggressive as we should be as the leading private provider of healthcare services in Finland in our pricing. But it is not only about headline prices. It involves a lot of other pricing actions, which have been yielding good results. What we see the CEO has done, and this is a continuous discussion with our commercial team, is that there's still room for us to maneuver on the commercial front. We have not as well. Maybe we can say that we have not emptied the tank yet. Of course, corporate companies are looking at the prices and they are considering the costs, but we continue to deliver value. And, as I said, we still have room to maneuver.

Katie Coxon
36:35 - 36:47

Great. Then maybe looking ahead to further development of the business, is there anything new that we could comment on regarding the digital offering or other new innovations? Perhaps something in the pipeline?

Ville Iho
36:49 - 37:53

In terms of the digital offering. And development on that front. We have followed the same logic as with the full turnaround program. Focus on delivering the agenda we already have in place. Not to start new projects. Too many new initiatives at the same time can be overwhelming. What we have seen this year, for example, is a good showcase of our steady progress. The AI-driven symptom screening tool that we have implemented for our corporate clients is one good example. It's a unique process at this stage for companies. And there's more to come. The focus will be both on customers and increasingly on professionals. Tools and efficiency gains in how professionals deliver services are being developed. We've made steady progress.

Katie Coxon
37:53 - 38:14

And I'm sure that we will discuss this topic at the upcoming Capital Markets Day in December as well. Now, a broader question. Which new business area might show unexpected growth potential in the foreseeable future? Do we have any examples of this?

Ville Iho
38:15 - 39:13

Well, in the last 20 months, we have played our cards well. The company and thousands of people in interviews have truly delivered. Now, as usual, we have the opportunity to dream bigger in the areas where we are already excelling. We will, of course, focus more on innovation and developing new types of services. In the next few years, we will concentrate on the same customer segments. We will create a base for potential public market growth whenever that happens. We continue to be the leading provider for consumers, insurance companies, and corporates alike. Development is always ongoing.

Katie Coxon
39:16 - 39:23

With that, I don't think we have any further questions, perhaps just some closing words and thank yous.

Juuso Pajunen
39:25 - 39:31

I wish everyone a very pleasant and hot summer. At least as hot as our numbers. Thank you.

Ville Iho
39:33 - 39:48

Thanks a lot for tuning in. And my special thanks to the team and our customers. These past 20 months have been successful, but there's more to come.

Katie Coxon
39:49 - 39:52

Great. Thank you for joining. Have a nice summer.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…